[HTML][HTML] Use of direct oral anticoagulants in daily practice

F Almarshad, A Alaklabi, E Bakhsh… - American journal of …, 2018 - ncbi.nlm.nih.gov
In recent years, the options for anticoagulant therapy have examined new direct oral
anticoagulants (DOACs) comprising direct thrombin inhibitors (dabigatran) and direct factor …

New oral anticoagulants in the treatment of acute venous thromboembolism–a systematic review with indirect comparisons

M Hirschl, M Kundi - Vasa, 2014 - econtent.hogrefe.com
Background: For decades, heparins and vitamin K antagonists (VKAs) have been the gold
standards in therapy of venous thromboembolism (VTE). The advent of factor IIa and Xa …

Facile-one pot-green synthesis, antibacterial, antifungal, antioxidant and antiplatelet activities of lignin capped silver nanoparticles: A promising therapeutic agent

MB Marulasiddeshwara, SS Dakshayani… - Materials Science and …, 2017 - Elsevier
The current work portrays the green synthesis of Lignin Capped Silver Nanoparticles
(LCSN) and their antibacterial, antifungal, antioxidant and antiplatelet potential. The LCSN …

Efficient synthesis and in silico studies of the benzimidazole hybrid scaffold with the quinolinyloxadiazole skeleton with potential α-glucosidase inhibitory …

SS Bharadwaj, B Poojary, SKM Nandish… - ACS …, 2018 - ACS Publications
The current study evaluates antidiabetic, anticoagulant, and antiplatelet activity of novel
benzimidazole-containing quinolinyl oxadiazoles. These derivatives are synthesized and …

[HTML][HTML] Direct oral anticoagulants are a potential alternative to low-molecular-weight heparin for thromboprophylaxis in trauma patients sustaining lower extremity …

CJ Nederpelt, KA Breen, MW El Hechi, P Krijnen… - Journal of Surgical …, 2021 - Elsevier
Background Trauma patients are at a significant risk of venous thromboembolism (VTE), with
lower extremity fractures (LEF) being independent risk factors. Use of direct oral …

Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and …

PL Mar, D Familtsev, MD Ezekowitz… - International journal of …, 2016 - Elsevier
An increasing number of individuals are on novel oral anticoagulants (NOAC) for
anticoagulation instead of vitamin K antagonists (VKA) and roughly 10% of these individuals …

Anticoagulant, antiplatelet and fibrin clot hydrolyzing activities of flax seed buffer extract

SKM Nandish, J Kengaiah, C Ramachandraiah… - Pharmacognosy …, 2018 - phcog.com
Background: Flax seeds possess long array of medicinal qualities as it found to show
beneficial effects on cardiovascular, hypertension, diabetes, cancer, inflammatory and …

Prophylaxis for venous thromboembolic events in Elective Total hip and total knee arthroplasty

T Karasavvidis, V Bouris, W Xiang… - Current …, 2022 - ingentaconnect.com
Venous thromboembolism (VTE) is a serious complication after major orthopaedic
operations, such as a total hip (THA) and knee (TKA) arthroplasty. Therefore, perioperative …

[HTML][HTML] Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation

YC Lau, Q Xiong, E Shantsila, GYH Lip… - Journal of thrombosis and …, 2016 - Springer
Non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin and heparins
in several clinical situations. With varying modes of action, the effects of NOACs on thrombus …

Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban or enoxaparin

AL Ricket, DW Stewart, RC Wood… - Annals of …, 2016 - journals.sagepub.com
Background: The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous
Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg …